Hematopoiesis News Volume 13.11 | Mar 22 2022

    By
    Justin.choi
    -
    0
    19







    2022-03-22 | HN 13.11


    Hematopoiesis News by STEMCELL Technologies
    Vol. 13.11 – 22 March, 2022
    TOP STORY

    Epigenetic Activation of Plasmacytoid DC Drives IFNAR-Dependent Therapeutic Differentiation of AML

    In models of AML, leukemia cell differentiation and therapeutic benefit mediated by the histone deacetylases inhibitor panobinostat required activation of the type I interferon pathway.
    [Cancer Discovery]

    Abstract
    How to prioritize and manage your research projects
    PUBLICATIONSRanked by the impact factor of the journal

    Hematopoietic Stem Cells Temporally Transition to Thrombopoietin Dependence in the Fetal Liver

    Investigators found that HSCs temporally transitioned to depend on thrombopoietin, a key extrinsic factor, from E16.5 onward in the developing liver.
    [Science Advances]

    Full Article

    Reductive TCA Cycle Catalyzed by Wild-Type IDH2 Promotes Acute Myeloid Leukemia and Is a Metabolic Vulnerability for Potential Targeted Therapy

    The role of wild-type isocitrate dehydrogenase-2 (IDH2) in AML cell survival and proliferation was tested using genetic knockdown and pharmacological inhibition in AML cells and animal models.
    [Journal of Hematology & Oncology]

    Full Article

    Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML

    The authors established cells with acquired resistance to the allosteric SHP2 inhibitor SHP099 from two FLT3-ITD-positive AML cell lines.
    [Cancer Research]

    Abstract

    A Self-Assembled Leucine Polymer Sensitizes Leukemic Stem Cells to Chemotherapy by Inhibiting Autophagy in Acute Myeloid Leukemia

    Investigators found that AML cells obtained from relapsed patients had increased autophagy levels than de novo AML cells.
    [Haematologica]

    Abstract

    Syndromes Predisposing to Leukemia Are a Major Cause of Inherited Cytopenias in Children

    Scientists used Sanger sequencing of commonly mutated genes and a custommade targeted next-generation sequencing panel covering 226 genes known to be mutated in inherited cytopenias; the minority subsequently underwent whole exome sequencing.
    [Haematologica]

    Abstract

    DDX41 Is Needed for Pre- and Postnatal Hematopoietic Stem Cell Differentiation in Mice

    The authors demonstrated that DDX41 was required for mouse HSC and progenitor cell survival and differentiation, particularly of myeloid lineage cells.
    [Stem Cell Reports]

    Full ArticleGraphical Abstract

    Acute Myeloid Leukemia Cells Functionally Compromise Hematopoietic Stem/Progenitor Cells Inhibiting Normal Hematopoiesis through the Release of Extracellular Vesicles

    Investigators found that AML cells released a heterogeneous population of extracellular vesicles containing microRNAs involved in AML pathogenesis.
    [Frontiers in Oncology]

    Full Article

    A Phase II Study of Sorafenib Combined with Conventional Therapies in Refractory Central Nervous System Leukemia

    To explore the efficacy of sorafenib combined with conventional therapies for refractory central nervous system leukemia, a Phase II study was conducted.
    [Cancer]

    Abstract

    Plasma Proteome Profiling Combined with Clinical and Genetic Features Reveals the Pathophysiological Characteristics of β-Thalassemia

    Researchers systematically conducted a comparative plasma proteomic profiling on β-thalassemia patients and healthy controls. Among 246 dysregulated proteins, 13 core protein signatures with excellent biomarker potential were proposed.
    [iScience]

    AbstractFull ArticleGraphical Abstract
    Request your free copy of the 'Directed Differentiation of Pluripotent Stem Cells' Wallchart
    REVIEWS

    Immunological Barriers to Hematopoietic Stem Cell Gene Therapy

    Recent clinical successes for gene therapies involving autologous HSC transplantation demonstrate the potential of genetic engineering in this stem cell type for curing disease.
    [Nature Reviews Immunology]

    Full Article

    Hematopoietic Responses to SARS-CoV-2 Infection

    The author reviews some of the key pathways including the infectious and inflammatory processes that control hematopoiesis, followed by a comprehensive review that summarizes the latest evidence and discusses how SARS-CoV-2 infection impacts hematopoiesis.
    [Cellular and Molecular Life Sciences]

    Full Article

    The Role of miRNAs as a Big Master Regulator of Signaling Pathways Involved in Lymphoblastic Leukemia

    Scientists summarize the potential miRNAs, especially circulating ones, involved in essential signaling pathways in acute lymphocytic leukemia and chronic lymphocytic leukemia patients which serve as biomarkers and valuable targets in the treatment fields.
    [Journal of Cellular Physiology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Wugen Announces First Patient Dosed in Phase I/II Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL

    Wugen, Inc. announced that the first patient has been dosed in a Phase I/II trial of WU-CART-007 for the treatment of relapsed or refractory (R/R) T cell acute lymphoblastic leukemia (T-ALL)/lymphoblastic lymphoma (LBL).
    [Wugen, Inc.]

    Press Release

    ORYZON Announces FDA Approval of IND for FRIDA, a Phase Ib Trial with Iadademstat in R/R AML FLT3mut+ Patients

    Oryzon Genomics, S.A. announced that it has received notification from the US FDA that its Investigational New Drug application (IND) for iadademstat is now approved to initiate a Phase Ib clinical trial in patients with relapsed/refractory (R/R) AML harboring a FMS-like tyrosine kinase mutation (FLT3mut+ ).
    [Oryzon Genomics, S.A.]

    Press Release
    FEATURED EVENT

    13th Online Dutch Stem Cell Meeting

    April 16, 2022
    Virtual

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Leukemia Subtypes

    University Children’s Hospital of Zurich – Zurich, Switzerland

    Postdoctoral Research Associate – Hematology/Oncology

    University of Illinois Chicago – Chicago, Illinois, United States

    Senior Staff Scientist – Primary Cells

    Wellcome Sanger Institute – Cambridge, United Kingdom

    Project Scientist – Division of Cardiovascular Medicine

    The University of California, Davis – Davis, California, United States

    Postdoctoral Scientist – Cellular Immunology/T Cell Therapy

    TU Dresden – Dresden, Germany

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter